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lopidogrel
inking Evaluation of
latelet Response Variability
o Mechanism of Action*
ndrew L. Frelinger III, PHD,†‡§
lan D. Michelson, MD†§
orcester, Massachusetts
he antiplatelet agent clopidogrel, given alone or in addi-
ion to aspirin, is effective in reducing the composite end
oint of death from cardiovascular causes, nonfatal myocar-
ial infarction, or stroke in patients with acute coronary
yndromes (1–3). However, many patients receiving clopi-
ogrel still sustain these poor outcomes. Furthermore,
aboratory assays of platelet response(s) to clopidogrel show
ide interindividual variability, with some patients being
lassified as “nonresponders” or “resistant” to clopidogrel
4–9). In this issue of the Journal, Labarthe et al. (10) show
hat some patients identified as nonresponders by one assay
re responders to clopidogrel by another assay. Understand-
ng why these assays give such different results is essential to
heir possible future utility as guides to therapeutic decision-
aking and new drug development.
See page 638
The spontaneous disruption of atherosclerotic plaque or
echanical injury of an artery (as occurs during percutane-
us coronary intervention) exposes the subendothelial ex-
racellular matrix proteins von Willebrand factor and colla-
en to blood, leading to platelet adhesion and activation.
nce activated, platelets aggregate with one another and
elease secondary platelet agonists, including adenosine
iphosphate (ADP), that in turn recruit additional platelets
o the growing thrombus. Two platelet ADP receptors,
nitially characterized by their pharmacologic profiles, have
ow been cloned and characterized: P2Y1 (11–13), which is
esponsible for platelet shape change, phospholipase C
ctivation, and calcium flux; and P2Y12 (14–16), which is
esponsible for the inhibition of adenylyl cyclase. P2Y12 has
urther been identified as the platelet ADP receptor targeted
y thienopyridines such as clopidogrel (14). Both P2Y1 and
2Y12 are seven-transmembrane domain G-protein–
oupled receptors, with P2Y1 coupled to Gq and P2Y12
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Departments of †Pediatrics and ‡Molecular Genetics and Microbiology,
nd the §Center for Platelet Function Studies, University of Massachusetts Medicalt
chool, Worcester, Massachusetts. Drs. Frelinger and Michelson have received
esearch support from Eli Lilly, Bristol-Myers Squibb/Sanofi-Aventis, and BioCytex.oupled to Gi2. Coactivation of Gq and Gi, and the
ignaling pathways they trigger, is necessary for full ADP-
nduced platelet aggregation (17).
When P2Y12 function is completely eliminated, as in the
ase of a patient with a defective form of the P2Y12 gene
18) or in platelets from P2Y12-null mice (16), limited
latelet aggregation still occurs unless other Gi-coupled
eceptors also are inhibited. However, this aggregation is
apidly reversible, demonstrating an important role for
2Y12 in the stabilization of platelet aggregation. Consis-
ent with this role in stabilizing platelet aggregation, P2Y12
unlike P2Y1) is not desensitized within seconds after
xposure to ADP but remains active over a longer period of
ime, thereby maintaining intracellular cyclic adenosine
onophosphate at reduced levels (19,20). The functional
onsequences of these receptor-mediated pathways are that
lthough both P2Y1 and P2Y12 are necessary for maximal
latelet aggregation, partial inhibition of P2Y12 has less of
n effect on maximal aggregation and more of an effect on
tabilization of aggregation. Therefore, assessing maximal
latelet aggregation as an end point for functional inhibition
f P2Y12 by thienopyridines may not be ideal and may be
urther complicated by variations in the level of P2Y1
unction or in the function of receptors other than P2Y12
such as alpha2-adrenergic receptors) that are capable of
riggering the Gi pathway. Indeed, polymorphisms in P2Y1
ecently have been found to be associated with increased
latelet response to ADP (21) and with increased arachi-
onic acid-stimulated platelet aggregation in patients with a
istory of myocardial infarction (22).
Labarthe et al. (10) observe that inhibition of multiple
nd points of ADP-stimulated platelet activation by clopi-
ogrel is more pronounced: 1) in blood anticoagulated with
ntithrombins (a mix of Phe-Pro-Arg-chloromethylketone
PPACK] and hirudin) rather than citrate, and 2) with an
nd point of late (stable) platelet aggregation rather than
aximal aggregation. These results suggest that PPACK/
irudin anticoagulant and late aggregation provide a more
ensitive means to test an individual’s pharmacologic re-
ponse to clopidogrel than previously used tests. In addition,
ecause P2Y12 and P2Y1 play different roles in maximal
ggregation versus late aggregation, the relative inhibition of
hese end points may provide information regarding the
nderlying pathogenesis in individuals with poor clinical
utcomes despite treatment with clopidogrel. Accordingly,
oor inhibition of maximal platelet aggregation combined
ith poor inhibition of late platelet aggregation may be the
onsequence of reduced bioavailability of clopidogrel, which
ay be overcome by increasing the clopidogrel dose. This
ossibility could be tested by guided therapy studies. Alter-
atively, poor inhibition of maximal aggregation, combined
ith significant inhibition of late aggregation, would sug-
est adequate inhibition of P2Y12 and implicate P2Y1 as a
arget for therapeutic intervention.
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August 16, 2005:646–7 Editorial CommentThe importance of the anticoagulant for testing antiplate-
et drugs has been appreciated since it was observed that the
lycoprotein IIb/IIIa antagonist eptifibatide is approxi-
ately two-fold less potent in blood anticoagulated with
PACK rather than citrate (23). The underlying mecha-
ism for increased clopidogrel inhibition of platelet activa-
ion markers in blood anticoagulated without calcium che-
ation is unclear. Labarthe et al. (10) found that combining
PACK/hirudin anticoagulant with the late aggregation
nd point resulted in an almost six-fold difference in the
stimation of the incidence of clopidogrel nonresponse
35% in citrate vs. 6% in PPACK/hirudin). Several mech-
nisms have been proposed to account for nonresponse to
lopidogrel, including drug interactions (24) and genetic
olymorphisms in the enzymes responsible for converting
lopidogrel into its active form (25).
Because PPACK/hirudin mimics in vivo conditions by
aintaining physiologic calcium levels and because late
ggregation more specifically reflects the pharmacologic
ffects of clopidogrel, this assay (rather than maximal
ggregation in citrate) may provide more relevant pharma-
odynamic information on which to base treatment changes.
owever, pharmacodynamic efficacy is not necessarily di-
ectly proportional to clinical efficacy. Small studies have
valuated the association of clinical outcomes with several
arkers of clopidogrel inhibition, including the inhibition
f maximal platelet aggregation in citrate (7) and
asodilator-stimulated phosphoprotein phosphorylation (4).
owever, the definitive answer as to which test is the best
arker of clinical efficacy will require correlation of these
aboratory tests with clinical outcomes in large clinical trials
f patients treated with clopidogrel.
eprint requests and correspondence: Dr. Andrew L. Frelinger
II, Pediatrics and Molecular Genetics and Microbiology, Univer-
ity of Massachusetts Medical School, 55 Lake Avenue North,
5-853, Worcester, Massachusetts 01655. E-mail: frelinger@
latelets.org.
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